NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
Clinical Trials
94 trialsNCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03937635 2026-03-02
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-03-02
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05243797 2026-02-17
MajesTEC-4
European Myeloma Network B.V.
Phase 3 Recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT06932562 2026-01-23
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT06237803 2025-12-03
EMN36
European Myeloma Network B.V.
Recruiting
NCT06649695 2025-09-25
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Phase 2 Recruiting
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03499808 2025-09-09
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT04617925 2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2 Completed
NCT07085728 2025-08-22
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT07107529 2025-08-12
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Not yet recruiting
NCT03896737 2025-08-11
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT06171685 2025-07-15
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Multiple Myeloma Research Consortium
Phase 2 Recruiting
NCT05123131 2025-07-08
Isa-RVD
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT05208086 2025-05-23
RHUMM
Intergroupe Francophone du Myelome
Recruiting
NCT06062537 2025-05-23
TEC-CARE
Intergroupe Francophone du Myelome
Active not recruiting
NCT04166565 2025-04-17
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT04483739 2025-02-26
IsKia
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03683277 2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2 Terminated
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT04150965 2025-02-14
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium
Phase 1/2 Terminated
NCT05944783 2025-02-12
BE-Dasatinib
Centro de Atencion e Investigacion Medica
Phase 4 Not yet recruiting
NCT04667663 2025-01-09
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT01903811 2024-12-20
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT04934475 2024-11-07
MIDAS
Intergroupe Francophone du Myelome
Phase 3 Active not recruiting
NCT06183489 2024-10-18
ERASMM
European Myeloma Network B.V.
Phase 2 Recruiting
NCT06189833 2024-04-23
TAURUS
European Myeloma Network B.V.
Phase 2 Recruiting
NCT01190787 2024-01-23
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
European Myeloma Network B.V.
Phase 2 Completed
NCT01913730 2023-12-13
Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
Phase 2 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04805203 2023-10-19
Covimmunomm
Intergroupe Francophone du Myelome
Phase NA Terminated
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT05082675 2023-09-11
Stem Cell Translpantation in Multiple Myeloma
European Society for Blood and Marrow Transplantation
Phase 2 Completed
NCT01346787 2023-09-08
CCD
European Myeloma Network B.V.
Phase 2 Completed
NCT03127761 2023-08-30
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Center for International Blood and Marrow Transplant Research
Recruiting
NCT02597062 2023-08-28
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00305812 2023-08-04
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01145989 2023-08-04
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02204241 2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2 Completed
NCT00003353 2023-06-22
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00014508 2023-06-22
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00052884 2023-06-18
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Eastern Cooperative Oncology Group
Phase 1 Terminated